Evoke Pharma, Inc. (EVOK)
| Previous close | 0.3007 |
| Open | 0.3034 |
| Bid | 0.2951 x 4000 |
| Ask | 0.3000 x 800 |
| Day's range | 0.2848 - 0.3034 |
| 52-week range | 0.2260 - 1.5800 |
| Volume | |
| Avg. volume | 4,838,970 |
| Market cap | 11.979M |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2650 |
| Earnings date | 10 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.50 |
- GlobeNewswire
Patient Experience Survey Reported Positive Findings for GIMOTI®
Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTISOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced positive findings from the first patient-centered survey related to GIMOTI. Following the series of market
- GlobeNewswire
Evoke Pharma to Present at H.C. Wainwright Global Investment Conference
SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray, today announced that its management team will present at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022. The presentation will be virtual and will provide an overview of the comm
- GlobeNewswire
Evoke Pharma Reports First Quarter 2022 Financial Results
Several sales growth indicators increased over Q4, 2021: New Prescribers up 41%; Product delivered to patients up 39%; Net Revenue increased by 16%; Prescriptions written up 22%SOLANA BEACH, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2022, and recent corporate developments. “We are encou
